NCT06724809View on ClinicalTrials.gov

Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD

PHASE3RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 16, 2025

Primary Completion Date

November 9, 2026

Study Completion Date

November 9, 2026

Conditions
NMOSDNeuromyelitis Optica Spectrum Disorders
Interventions
DRUG

eculizumab

Participants will receive eculizumab by intravenous (IV) infusion for 52 weeks.

Trial Locations (10)

100016

RECRUITING

Research Site, Beijing

110004

WITHDRAWN

Research Site, Shenyang

200040

RECRUITING

Research Site, Shanghai

250012

RECRUITING

Research Site, Jinan

325000

RECRUITING

Research Site, Wenzhou

430030

RECRUITING

Research Site, Wuhan

430060

RECRUITING

Research Site, Wuhan

450003

WITHDRAWN

Research Site, Zhengzhou

523059

RECRUITING

Research Site, Dongguan

030001

RECRUITING

Research Site, Taiyuan

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Alexion Pharmaceuticals, Inc.

INDUSTRY